title: Significance of complement split product C4d in ABO-compatible liver allograft: diagnosing utility in acute antibody mediated rejection.
abstract: Diagnosis of liver allograft antibody-mediated rejection (AMR) is difficult and requires a constellation of clinical, laboratory and histologic features that support the disease and exclude other causes. Histologic features of AMR may intermix with those of biliary obstruction, preservation/reperfusion injury, and graft ischemia. Tissue examination for complement degradation product 4d (C4d) has been proved to support this diagnosis in other allografts. For this reason, we conducted a retrospective review of all ABO compatible/identical re-transplanted liver patients with primary focus on identifying AMR as a possible cause of graft failure and to investigate the utility of C4d in liver allograft specimens. We reviewed 193 liver samples obtained from 53 consecutive ABO-compatible re-transplant patients. 142 specimens were stained with C4d. Anti-donor antibody screening and identification was determined by Luminex100 flow cytometry. For the study analysis, patients were stratified into 3 groups according to time to graft failure: group A, patients with graft failure within 0-7 days (n=7), group B within 8-90 days (n=13) and C >90 days (n=33). Two patients (3.7%) met the diagnostic criteria of acute AMR. Both patients experienced rapid decline of graft function with presence of donor specific antibodies (DSA), morphologic evidence of humoral rejection and C4d deposition in liver specimens. C4d-positive staining was identified in different medical liver conditions i.e., acute cellular rejection (52%), chronic ductopenic rejection (50%), recurrent liver disease (48%), preservation injury (18%), and hepatic necrosis (54%). Univariate analysis showed no significant difference of C4d-positive staining among the 3 patients groups, or patients with DSA (P>.05). In conclusion, AMR after ABO-compatible liver transplantation is an uncommon cause of graft failure. Unlike other solid organ allografts, C4d-positive staining is not a rugged indicator of humoral rejection, thus, interpretation should be done with caution to avoid diagnostic dilemmas.
authors: Henry Ford Hospital, USA. alisa@upmc.edu
authors: Sharif
authors: S
authors: Ali
authors: Adrian
authors: A
authors: Ormsby
authors: Veena
authors: V
authors: Shah
authors: Maria C
authors: MC
authors: Segovia
authors: Kristin L
authors: KL
authors: Kantz
authors: Sharon
authors: S
authors: Skorupski
authors: A Bradley
authors: AB
authors: Eisenbrey
authors: Meredith
authors: M
authors: Mahan
authors: Mary Ann Y
authors: MA
authors: Huang
mesh_terms: D000017:ABO Blood-Group System / Q000276:immunology*; D015415:Biomarkers; D015935:Complement C4b / Q000276:immunology* / Q000378:metabolism; D005260:Female; D006084:Graft Rejection / Q000175:diagnosis* / Q000276:immunology; D006650:Histocompatibility Testing; D006651:Histocytochemistry; D006801:Humans; D007518:Isoantibodies / Q000276:immunology*; D008099:Liver / Q000473:pathology; D016031:Liver Transplantation / Q000276:immunology* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D010446:Peptide Fragments / Q000276:immunology* / Q000378:metabolism; D012189:Retrospective Studies; D014019:Tissue Donors; D014184:Transplantation, Homologous / Q000276:immunology; D016896:Treatment Outcome
chemical_list: D000017:ABO Blood-Group System; D015415:Biomarkers; D007518:Isoantibodies; D010446:Peptide Fragments; D015935:Complement C4b; C032261:complement C4d